Efficacy and Safety of HL-085 in Patients With Advanced Melanoma Harboring NRAS Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
BMC Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
BMC Med 2023 Jan 04;21(1)2, X Wang, Z Luo, J Chen, Y Chen, D Ji, L Fan, L Chen, Q Zhao, P Hu, P Sun, Z Jia, J Guo, L SiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.